INTRODUCTION
============

Alzheimer\'s disease (AD) is the most common form of adult dementia and is characterized by progressive cognitive deterioration, impairment of activities of daily living, and a variety of neuropsychiatric symptoms and behavioral disturbances. It is generally accepted that the production and accumulation of beta-amyloid peptide in the brain in AD are important in the pathogenesis of the disease ([@B1]). Increasing evidence supports that mutations in the beta-amyloid precursor protein and the presenilins lead to some early-onset AD cases ([@B1]). Although mutations can be induced by numerous endogenous and exogenous agents, oxidative stress has been thought to be the main source for DNA damage in AD ([@B2]). Indeed, previous studies have demonstrated that increased nuclear and mitochondrial DNA oxidation is present in the brain in AD ([@B3; @B4; @B5; @B6]), with 8-hydroxyguanine or its isomeric form 7,8-dihydro-8-oxoguanine (8-oxoG) being the major DNA lesion ([@B7]).

The 8-oxoG is highly mutagenic because adenine is preferentially incorporated opposite the oxidized base upon replication by DNA polymerases, yielding GC to TA transversions. To prevent 8-oxoG-induced mutagenesis, cells possess a mechanism called the GO system, which consists of MutY homolog (MYH), OGG1 (8-oxoG-DNA glycosylase I, the eukaryotic homolog of MutM), and MutT ([@B8; @B9; @B10]). The MutT protein is a phosphotase that specifically converts 8-oxo-dGTP in the nucleotide pool into 8-oxo-dGMP to keep the oxidized nucleotides from being incorporated into DNA during replication. Both MYH and OGG1 are 8-oxoG-specific DNA glycosylases. Unlike MutT, OGG1 and MYH are components of base excision repair and involved in processing 8-oxoG ([@B9],[@B10]). Whereas, OGG1 actually removes 8-oxoG from damaged DNA, MYH excises the adenine residues incorporated by DNA polymerases opposite 8-oxoG. Mutations of OGG1 and MYH have been implicated in the development of certain human diseases including cancer ([@B11; @B12; @B13]). Gene knockout mice defective in *OGG1* accumulate higher levels of 8-oxoG lesions compared with wild-type controls ([@B14],[@B15]), and exhibit elevated spontaneous mutations, especially when exposed to higher levels of oxidative stress ([@B16]). These observations suggest that OGG1 acts as a major pathway responsible for 8-oxoG removal ([@B17]).

To determine the impact of OGG1 in AD development, DNA and/or protein samples derived from the brain of AD patients and age-matched controls were analyzed for defects in *OGG1* and OGG1 glycosylase activity. Mutations of the *OGG1* gene were indeed identified in AD patients. Biochemical studies revealed that these mutations either completely inactivate or severely reduce the OGG1 DNA-glycosylase activity, suggesting that defects in OGG1 are associated with the development of AD.

MATERIALS AND METHODS
=====================

AD sample collection
--------------------

Brain specimens were from AD patients and normal control subjects who were longitudinally followed with annual detailed assessments in the University of Kentucky Alzheimer\'s Disease Center. The specimens were evaluated in a blinded manner in our study. These samples were collected as described previously ([@B3]). Briefly, 10--15 g specimens of frontal, temporal and parietal lobes and cerebellum were dissected en bloc at the time of autopsy from patients with AD and age-matched normal control subjects. The tissue was snap-frozen and stored at −70°C until used for analysis. All AD patients met standard clinical diagnostic criteria for probable AD ([@B18]) and accepted histopathological criteria for the diagnosis of AD ([@B19]). The AD patients were in the late stage of AD. Control subjects were individuals without a history of dementia, other neurological disorders or systemic disease affecting the brain. Neuropathological studies revealed no significant neuropathological alterations in the control subjects. The mean age for the control cases was 92.3 and 72.0 years for the AD cases. The average postmortem interval was 2.90 ± 0.31 h for AD and 3.36 ± 0.47 h for control subjects.

OGG1 activity assay
-------------------

Preparation of nuclear extracts from brain specimens was performed as described previously ([@B20]). Because of potential variations in water content in tissues collected from various individuals (both AD and control subjects), data were normalized to protein content for each isolated nuclear fraction, rather than using the same amount of starting materials for extract preparations. The OGG1 glycosylase activity was measured essentially as described ([@B21]) using an oligonucleotide duplex consisting of the ^32^P-labeled 5′-ATTGCCATTCTCGATA\[8-oxoG\]GATCCGGTCAAACCTAGAC-3′ and the cold complementary strand 5′ GTCTAGGTTTGACCGGATCCTATCGAGAATGGCAAT-3′. Briefly, incision reactions (20 μl) contained 50 mM sodium phosphate buffer (pH 6.8), 2 mM EDTA, 2 mM DTT, 80 mM KCl, 0.1 mg/ml of BSA, 10% glycerol, 50 fmol of ^32^P-labeled duplex and 40 μg of nuclear extracts or indicated amount of purified wild-type or mutant OGG1 protein. After incubation at 37°C for 1 h, the reactions were terminated by adding an equal volume of a stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylem cyanol). The reaction products were resolved on a 15% denaturing gel and visualized by a phosphorimager.

Site-directed mutagenesis, overexpression and purification of OGG1
------------------------------------------------------------------

The His-tagged human *OGG1* expression vector (pET28d) was kindly provided by Drs Sankar Mitra and Tapas K. Hazra, University of Texas Medical Branch at Galveston. Construction of the *OGG1* mutants associated with AD was performed using an overlap-extension PCR technology as described ([@B22]), which is depicted in [Figure 1](#F1){ref-type="fig"}, showing the strategy for the generation of the C~796~-deletion of *OGG1*. Two sets of PCR primers were used: forward primer 1 (RP1), 5′-GGGGAATTGTGAGCGGATAAC-3′, and reverse primer 1 (RP1), 5′-ATATGGACATCCAC**GG**CACAGCCTGGGGCTT-3′; FP2, 5′-AGGCTGTG**CC**GTGGATGTCCATATGT-3′ and RP2, 5′-GGTGGTGGTGGTGCTCGAG-3′, where the bold types represent the mutation site. PCR products from the two sets of reactions were mixed, denatured and reannealed. Because these PCR products overlapped at their 3′ ends, a full-length mutant *OGG1* was generated via 3′ end extension ([Figure 1](#F1){ref-type="fig"}). The full-length mutant gene was amplified using primers FP1 and RP2, digested with XhoI and XbaI, and cloned into the XhoI/XbaI-digested pET28d expression vector. The C~796~ deletion results in a frame-shift mutation that allows the mutated gene to encode a protein 59 amino acids longer than the wild-type OGG1 (see below for details). Thus, a pair of primers (5′-ACTGTCACTAGTCTCACCAG-3′ and 5′-ATACTCGAGTCAATATCCCCCACCCCATCTTGTTG-3′) were used to amplify part of the exon 7 sequence of *OGG1* and its 3′ untranslated region (3′-UTR) from genomic DNA derived from patient AD2. After digestion with BspMI and XhoI, the PCR product was cloned into pET28d plasmid containing the C~796~-deleted *OGG1*. The presence of the C~796~ deletion and the extended 3′UTR was confirmed by DNA sequencing. Other *OGG1* mutants identified in AD were similarly constructed. Figure 1.Diagram of PCR-based site-directed mutagenesis. Deletion of a C from C~796~ C~797~ C~798~ in *OGG1* is shown as an example.

The wild-type and mutant *OGG1* plasmids were transformed into *Escherichia coli* strain BL21 DE3 for expression and the recombinant proteins were purified as described by Hill *et al*. ([@B23]). The purified proteins (\>98% purity, as judged by Coomassie Brilliant Blue R-250 staining on an SDS-PAGE gel) were aliquoted and stored at −80°C for use.

Single-strand conformational polymorphism and DNA sequencing analyses
---------------------------------------------------------------------

Nuclear DNA was isolated from brain regions of AD patients and controls as described by Gabbita *et al*. ([@B3]). PCR-based single-strand conformation polymorphism (SSCP) was used to determine mutations in *OGG1*. PCR primers (Supplementary Data, Table S1) were used to amplify all seven exons and flanking splice sites of the *OGG1* gene as described by Murata *et al*. ([@B24]). Variant and wild-type PCR products were excised and eluted from SSCP gels, and then reamplified. The resulting PCR products were sequenced using T7 Sequenase, version 2.0 DNA sequencing kit (USB Corp., Cleveland, OH, USA).

Statistical analysis
--------------------

Statistical analyses were performed using *t*-test function in *R* package. Specifically, one-sided *t*-test was used to compare 8-oxoG glycosylase activity shown in [Figure 2](#F2){ref-type="fig"} and 8-oxoG lesion level in [Table 1](#T1){ref-type="table"}. Figure 2.The 8-oxoG glycosylase activity of nuclear extracts derived from brain of AD patients. Nuclear extracts (40 μg) from AD patients (AD1, AD2 and AD3) or age-matched controls (C1, C2 and C3) were incubated with 50 fmol of ^32^P-labeled 36-mer duplex containing a centrally located 8-oxoG residue. 8-oxoG cleavage activity in AD patients, except AD1, was lower than that in age-matched controls. Table 1.8-OxoG lesion levels in AD patients with and without OGG1 alterations[^a^](#TF1){ref-type="table-fn"}8-OxoG (lesions/10^6^ bases)OGG1 mutationAD patientAD2241.2FrameshiftAD4237.5A53TAD6171.9NoneAD7133.3NoneAD8192.5NoneControlC461.4NoneC570.0None[^1]

RESULTS
=======

Reduced 8-oxoG DNA glycosylase activity in AD patients
------------------------------------------------------

The abundance of 8-oxoG in the brain of AD patients prompted us to determine 8-oxoG glycosylase activity in AD patients. Nuclear extracts obtained from the brain specimens of AD patients were examined for their ability to cleave a duplex DNA containing a single 8-oxoG lesion. As shown in [Figure 2](#F2){ref-type="fig"}, the nuclear extracts derived from all three age-matched controls (C1, C2 and C3) exhibited high levels (8% or more) of 8-oxoG glycosylase activity, whereas extracts from two (AD2 and AD3) of the three AD patients tested had only about one-half of the glycosylase activity observed in the control samples. These results were repeatable. Statistical analysis revealed that the observed difference in glycosylase activity between extracts derived from AD patients with lower 8-oxoG glycosylase activity (AD2 and AD3) and those isolated from control subjects (C1-3) or an AD patient with normal glycosylase activity (i.e. AD1) is highly significant (*P* = 0.00298). These observations suggest that reduced repair of 8-oxoG is associated with AD patients.

*OGG1* mutations in AD patients
-------------------------------

Because the major DNA glycosylase for removal of 8-oxoG is OGG1 ([@B17]), we reasoned that the reduced 8-oxoG glycosylase activity in AD patients could be due to a reduction in OGG1 activity. PCR primers (Supplementary Data, Table 1) were therefore designed to amplify all seven individual exons of the *OGG1* gene from the brain specimens of AD patients and age-matched controls. The resulting PCR products were analyzed by SSCP as described ([@B24]). Whereas, no abnormal SSCP products were detected in exons 1-4, 6 and 7 of *OGG1* in all samples tested (data not shown), two AD patients appeared to display aberrant SSCP bands in exon 5. As shown in [Figure 3](#F3){ref-type="fig"}A, two specific products (bands 1 and 4), presumably the normal alleles of the *OGG1* exon 5, were seen in the age-matched controls (data for C1 and C2 not shown) and patient AD1 but both normal and additional alleles (bands 2 and 3) were detected in AD2 and AD3, the two AD patients exhibiting reduced 8-oxoG glycosylase activity ([Figure 2](#F2){ref-type="fig"}). These results seem to suggest a heterozygous alteration of *OGG1* in these patients. Figure 3.Mutations of *OGG1* identified in AD patients. (**A**) SSCP analysis of AD patients and age-matched controls. Whereas, samples with higher levels of 8-oxoG cleavage activity (AD1 and C3) exhibited two specific SSCP products (bands 1 and 4), samples with lower levels of 8-oxoG cleavage activity showed two additional products (bands 2 and 3). (**B**) C~796~ deletion in AD2 and AD3. The indicated SSCP bands from patients or controls were eluted, PCR-amplified and sequenced. (**C**) Base--base substitutions in AD4 and AD5. Arrows point to the altered nucleotides.

To determine if the abnormal SSCP products of exon 5 in AD2 and AD3 were associated with mutation(s), SSCP bands 1--4 shown in [Figure 3](#F3){ref-type="fig"}A were eluted from the gel, reamplified and sequenced. As expected, bands 1 and 4 from all samples indeed showed the wild-type *OGG1* sequence, and examples of these sequences are shown in [Figure 3](#F3){ref-type="fig"}B (see two gels on the left side for AD1 and C3). However, bands 2 and 3 exhibited a mutated *OGG1* sequence as a C (C~796~, C~797~ or C~798~) was deleted from nucleotide positions 796--798. For simplicity, the mutation was referred to as C~796~-deleted. Interestingly, both AD2 and AD3 carried the same deletion ([Figure 3](#F3){ref-type="fig"}B, two gels on the right side). The status of the heterozygous mutation in AD2 and AD3 was further confirmed by cloning the PCR products of exon 5 into a T-A cloning vector (Invitrogen, Carlsbad, CA, USA), followed by DNA sequencing. The results revealed an approximate 1:1 ratio of wild-type and mutant clones (data not shown).

The association of a defective *OGG1* in AD2 and AD3 prompted us to investigate 11 additional AD samples for mutations in *OGG1*. Abnormal SSCP products were identified in two patients (data not shown). DNA sequencing analysis revealed that one patient (AD4) had a G~157~→A transition and another patient (AD5) carried a C~863~→T transition in *OGG1* ([Figure 3](#F3){ref-type="fig"}C). The G→A substitution changes amino acid residue alanine~53~ (A~53~) to threonine and the C→T substitution changes alanine~288~ (A~288~) to valine. However, no nucleotide alterations were identified in any of the seven additional age-matched controls (C4 in [Figure 3](#F3){ref-type="fig"}C, data for C5--C10 not shown). Taken together, our results suggest that a substantial fraction (28.6% or 4 out of 14) of AD patients are associated with mutations in the *OGG1* gene.

The C~796~-deleted *OGG1* gene encodes a proteins lacking 8-oxoG glycosylase activity
-------------------------------------------------------------------------------------

Given a single nucleotide deletion in the *OGG1* gene, AD2 and AD3 were expected to express an altered OGG1 protein that possesses a carboxyl terminal different from that of the wild-type OGG1. The wild-type *OGG1* gene encodes 345 amino acid residues ([Figure 4](#F4){ref-type="fig"}A). However, the C~796~ deletion altered the coding frame of *OGG1* at the mutation site. As a result, the translation does not terminate at codon 346, instead, it terminates 59 amino acid residues downstream of the previous termination site ([Figure 4](#F4){ref-type="fig"}B). Thus, not only does the mutated protein contain different amino acid residues from the wild-type OGG1 following the mutation site, but also is 59-residue bigger than OGG1 ([Figure 4](#F4){ref-type="fig"}B). The mutant protein was therefore referred to as OGG1-59aa. Figure 4.Locations of the identified mutations in OGG1. (**A**) Partial protein and DNA sequences of wild-type OGG1. (**B**) Partial protein and DNA sequences of OGG1-59aa. Mutation site and original stop codon are highlighted. Recognition sequence of the restriction endonuclease BspMI is also highlighted, which was used to clone part of the exon 7 and 3′-UTR sequences from patient AD2 into pET28d plasmid. (**C**) Partial DNA and peptide sequences of mutants A53T and A288V. Important functional domains (modified from [www.sanger.ac.uk/cgi-bin/Pfam/swisspfamget.pl?name=O15527](www.sanger.ac.uk/cgi-bin/Pfam/swisspfamget.pl?name=O15527)) of OGG1 are also shown.

To determine if the mutated OGG1 retains 8-oxoG glycosylase activity, site-directed mutagenesis was performed to generate the OGG1-59aa as described in Materials and Methods section. Both the wild type and OGG1-59aa proteins were purified ([Figure 5](#F5){ref-type="fig"}A) and assayed for the 8-oxoG glycosylase activity. Whereas, the wild-type OGG1 (W) was very active in cleaving the 8-oxoG-containing duplex, little such activity was detected in reactions with OGG1-59aa (M), regardless of the reaction incubation time and the amount of protein used ([Figure 5](#F5){ref-type="fig"}B and C). Mixing experiments using various ratios of wild-type OGG1 versus OGG1-59aa indicated that the mutant protein had no negative inference on the wild-type OGG1 activity (data not shown), ruling out a dominant negative role for OGG1-59aa. These results indicate that a defective OGG1 is present in patients AD2 and AD3, which may account for the reduced 8-oxoG glycosylase activity in these patients. Figure 5.OGG1-59aa has no glycosylase activity. 8-OxoG glycosylase activity was determined as described in the [Figure 2](#F2){ref-type="fig"} legends, but using purified proteins. (**A**) SDS-PAGE of purified recombinant wild-type and mutant OGG1 proteins, as indicated. (**B**) 8-oxoG glycosylase activity of wild-type OGG1 (W) and OGG1-59aa (M) using the indicated amount of proteins. Reactions were incubated at 37°C for 30 min. (**C**) Time course of 8-oxoG glycosylase activity assays of OGG1 (W) and OGG1-59aa (M). Each reaction contained 1.25 fmol of the indicated proteins.

OGG1 with A53T or A288V substitution possesses a reduced 8-oxoG glycosylase activity
------------------------------------------------------------------------------------

To determine the impact of A53T or A288V substitution on OGG1 glycosylase activity, genes encoding OGG1(A53T) and OGG1(A288V) were created using a similar strategy as described in [Figure 1](#F1){ref-type="fig"}, and the mutant proteins were purified (see [Figure 5](#F5){ref-type="fig"}A) and examined for 8-oxoG glycosylase activity. Unlike OGG1-59aa, which is completely defective in 8-oxoG glycosylase activity, both OGG1(A53T) and OGG1(A288V) proteins were capable of cleaving the 8-oxoG-containing oligonucleotide duplex ([Figure 6](#F6){ref-type="fig"}A and B). However, the glycosylase activity of both altered proteins was only 50--60% of the wild-type OGG1 activity ([Figure 6](#F6){ref-type="fig"}C). Further analysis revealed that both mutant proteins possess a *K*~m~ higher than that of the wild-type OGG1 ([Figure 6](#F6){ref-type="fig"}D), indicating that the reduction in glycosylase activity for both mutant proteins is due to the reduction in enzyme\'s affinity to the DNA substrate. Although protein samples of patients AD4 and AD5 were not available for biochemical assays, our results strongly suggest that reduced 8-oxoG glycosylase activity was likely present in the brain of these AD patients. Figure 6.Reduced glycosylase activity in OGG1(A53T) and OGG1(A288V). Unless otherwise mentioned, 8-oxoG glycosylase activity was assayed in a 20-μl reaction containing 25 fmol of wild-type (W) or mutant (M) OGG1 and 50 fmol of oligonucleotide duplexes containing a single 8-oxoG. Reactions were incubated at 37°C for 1 h. (**A**) Time course of glycosylase activity of OGG1(A53T). (**B**) Time course of glycosylase activity of OGG1(A288)V. (**C**) Comparison of glycosylase activities among various OGG1 proteins. Each point represents the average value of three independent experiments, and error bars show SDs. (**D**) OGG1(A53T) and OGG1(A288V) possess a *K*~m~ that is higher than that of OGG1. Reactions were assembled similarly as described in panels A and B, but incubated at 37°C for 30 min and in the presence of increasing DNA concentrations as indicated.

DISCUSSION
==========

Patients with AD have been shown to exhibit a much higher level of 8-oxoG DNA lesions in brain than age-matched normal control subjects ([@B7]). The increased level of 8-oxoG lesions in AD is likely due to reduced DNA repair in these patients. We provide here both the genetic and biochemical evidence that a significant fraction (28.6%) of AD patients examined in this study exhibited mutations in the 8-oxoG removing gene *OGG1* and that OGG1 proteins with the mutations identified in AD patients have either no or greatly reduced 8-oxoG glycosylase activity.

Interestingly, of four unrelated patients with *OGG1* mutations, two (AD2 and AD3) had a C~796~ deletion mutation, which changes the *OGG1* reading frame and leads to a different carboxyl terminal sequence, including an extra fragment of 59 amino acid residues ([Figure 4](#F4){ref-type="fig"}). This mutation completely abolishes the OGG1 glycosylase activity ([Figure 5](#F5){ref-type="fig"}). This result is consistent with previous crystal structure studies of the human OGG1 protein. Bruner *et al*. ([@B25]) demonstrated that the 8-oxoG lesion is extruded from the DNA helix and inserted into an extrahelical pocket composed of amino acid residues Phe~319~, Gln~315~, Gly~42~ and Cys~253~ of OGG1. In this active-site pocket, Phe~319~ and Cys~253~ sandwich the 8-oxoG lesion via interactions with the lesion; the Gln~315~ amide-NH~2~ and a water molecule tightly bound to the residue cooperate to recognize O^6^ of the oxoG; and the side-chain carbonyl of Gln~315~ and a second tightly bound water form hydrogen bonds with N1, NH~2~ and O^6^ of the oxoG ([@B25]). In addition, residue Asp~268~ is required to deprotonate Lys~249~ and His~270~ is needed to protonate Lys~249~, which acts to displace the oxoG base and to promote conjugate elimination of the 3′ phosphodiester through Schiff base chemistry ([@B25]). However, the C~796~ deletion alters the *OGG1* reading frame beginning at amino acid residue 267, leading to a protein no longer containing these important residues (i.e. Asp~268~, His~270~, Gln~315~ and Phe~319~) at the corresponding positions (see [Figure 4](#F4){ref-type="fig"}A and B). Therefore, it is understandable that the OGG1-59aa has no 8-oxoG glycosylase activity.

Two additional OGG1 mutations, A53T and A288V, were also identified in AD patients and both were found to reduce 8-oxoG glycosylase activity ([Figure 6](#F6){ref-type="fig"}). The observed activities for these mutants appear to be justified by the roles of A~53~ and A~288~ in the OGG1 structure. OGG1 has two important domains (see [Figure 4](#F4){ref-type="fig"}C): the OGG-N domain partially contributes to the 8-oxoG-binding pocket and the HhH-GPD domain (a helix--hairpin--helix structural element followed by a Gly/Pro-rich loop and a conserved aspartic acid) provides both the catalytic and DNA-binding functions of the DNA glycosylase ([@B26; @B27; @B28]). A~53~ is located in the region linking two β sheets (β B and β C) in the OGG-N domain, and A~288~ is part of the polypeptide connecting two α-helices (α M and α N) involved in the catalytic activity of the glycosylase ([@B25]). Thus, both alanine residues are not in the active center of their corresponding domains. However, substitutions of these alanines with other residues may allow OGG1 to adapt a conformation that is slightly different from the wild-type conformation, leading to the observed reduced glycosylase activity. Whether or not these alterations represent polymorphism in the population remains to be defined. It is also important to determine if individuals with these types of OGG1 alterations are at higher risk to develop AD.

It is interesting that, although a defective OGG1 was detected in the brain of patients AD2 and AD3, extracts derived from these tissues still contained partial 8-oxoG glycosylase activity ([Figure 2](#F2){ref-type="fig"}). This phenomenon could be attributed to two possibilities. First, the alteration is a heterozygous mutation, thus, the patients possessed both wild-type and mutant OGG1. This possibility is supported by the fact that both wild-type and mutant alleles of the *OGG1* exon 5 were detected in patients AD2 and AD3 ([Figure 3](#F3){ref-type="fig"}A) and that the mutant OGG1 protein does not interfere with the wild-type protein on its glycosylase activity (data not shown). A second explanation is that there are multiple 8-oxoG glycosylase activities in human cells. Evidence for this assumption came from gene knockout mice defective in *OGG1*. Although *Ogg1*^−/−^ mice manifest a steady-state level of 8-oxoG that is 3- to 10-fold higher than wild-type controls ([@B14],[@B15]), there is slow but significant removal of 8-oxoG from proliferating *Ogg1*-null cells ([@B29]), indicating that alterative 8-oxoG repair pathways are present in mammalian cells. Indeed, such activities have been recently identified ([@B17],[@B30]).

The presence of multiple 8-oxoG glycosylase activities in mammalian cells may also explain why some AD patients who were previously shown to exhibit higher levels of 8-oxoG lesions in brain ([@B3; @B4; @B5; @B6]) seemed to be normal in OGG1 glycosylase activity, implying that deficiency in other 8-oxoG removal pathway(s) may also contribute to the high level of 8-oxoG in AD. Previous studies have shown significant differences in 8-oxoG levels between AD patients and age-matched controls ([@B3; @B4; @B5; @B6]). Interestingly, when 8-oxoG levels reported previously ([@B3; @B4; @B5; @B6]) were compared between AD patients with and without *OGG1* mutations, it was found that the 8-oxoG level in AD with *OGG1* alterations was higher than that in those without *OGG1* alterations ([Table 1](#T1){ref-type="table"}). And *t*-test analysis revealed that the difference in 8-oxoG levels between these two groups is highly significant as judged by *P* = 0.025. These data indicate that whereas OGG1 is the major 8-oxoG removal enzyme, abnormality in other 8-oxoG removal pathway(s), and 8-oxoG tolerance (MYH) and cleansing (MutT homologs) pathways can also result in accumulation of the oxidized lesion. The identification of only 28.6% AD patients with OGG1 alterations also support the possibility that the remaining 71.4% of the AD patients could have mutations in MYH, MutT homologs and/or other 8-oxoG removal pathways. Although this hypothesis remains to be investigated, our results shown here indicate that defects in DNA repair, including the OGG1 pathway, are present in AD patients, providing a possible molecular basis for the development of AD.

SUPPLEMENTARY DATA
==================

Supplementary Data are available at NAR online.
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